In this free webinar, learn what clinical in-use studies are and why they matter for biologics safety, efficacy and CMC lifecycle. Attendees will gain insight intoIn this free webinar, learn what clinical in-use studies are and why they matter for biologics safety, efficacy and CMC lifecycle. Attendees will gain insight into

Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn what clinical in-use studies are and why they matter for biologics safety, efficacy and CMC lifecycle. Attendees will gain insight into designing clinical in-use studies and primary considerations. The featured speakers will discuss analytical method selection for the assessment of critical quality attributes. The speakers will also share compatibility and device considerations (e.g., diluents, IV lines, filters, syringes and infusion bags). Attendees will learn about translating results into labelling, pharmacy SOPs and risk versus benefit decisions.

TORONTO, Jan. 7, 2026 /PRNewswire/ — As biotherapeutics leave the controlled environment of the manufacturing facility and enter real-world clinical trials, the risk of failure due to lack of efficacy could be as high as 50%. This can be de-risked by evaluating how stressors during preparation and administration may affect therapy, using clinical in-use studies during drug product process development.

This webinar explores how clinical mimic studies sit at the intersection of stability, compatibility, handling and patient safety. The featured speakers will focus on the risks of aggregation, adsorption, subvisible particles and functional loss and will introduce considerations that accompany reconstitution, dilution and storage. Real case examples will be presented to highlight common failure modes and mitigation strategies to enable safe and efficient clinical use.

Participants will learn approaches to design robust, fit-for-purpose clinical in-use protocols aligned with evolving regulatory expectations (WHO, FDA, EMA and USP), selection of appropriate physicochemical and biophysical analytical methods and interpretation of data to support decision making and risk management with respect to clinical administration of biotherapeutic drug products.

Register for this webinar to learn how clinical in-use studies contribute to clinical trial success by strengthening the safety, efficacy and reliability of biotherapeutic drug administration.

Join experts from FUJIFILM Biotechnologies, Daniel Pettit, Head of Analytical Development; and Natalia Harasimiuk, Director of Analytical Services, for the live webinar on Thursday, January 22, 2026, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bridging-bench-to-bedside-derisking-biotherapeutic-administration-via-cdmoled-clinicalmimic-and-inuse-testing-strategies-upcoming-webinar-hosted-by-xtalks-302654658.html

SOURCE Xtalks

Market Opportunity
Octavia Logo
Octavia Price(VIA)
$0.0125
$0.0125$0.0125
-8.75%
USD
Octavia (VIA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Lindy AI vs. SuperCool: Task Automation vs. Autonomous Creation

Lindy AI vs. SuperCool: Task Automation vs. Autonomous Creation

Lindy AI and SuperCool are both AI-powered platforms designed to help people get work done faster, but they operate at very different layers of the AI ecosystem
Share
AI Journal2026/01/12 12:37
US Dollar Index falls to near 99.00 amid Fed probe, rate cut doubts

US Dollar Index falls to near 99.00 amid Fed probe, rate cut doubts

The post US Dollar Index falls to near 99.00 amid Fed probe, rate cut doubts appeared on BitcoinEthereumNews.com. The US Dollar Index (DXY), which measures the
Share
BitcoinEthereumNews2026/01/12 11:52
Best Crypto to Buy as ChatGPT Predicts Bitcoin Will Explode After Rate Cuts

Best Crypto to Buy as ChatGPT Predicts Bitcoin Will Explode After Rate Cuts

The post Best Crypto to Buy as ChatGPT Predicts Bitcoin Will Explode After Rate Cuts appeared on BitcoinEthereumNews.com. Best Crypto to Buy as ChatGPT Predicts Bitcoin Will Explode After Rate Cuts Sign Up for Our Newsletter! For updates and exclusive offers enter your email. Aidan Weeks, a Master’s graduate in Mechanical Engineering, has thrived as a content writer for over four years. Specializing in crypto, tech, engineering, AI, and B2B sectors, Aidan adeptly crafts web copy, blog posts, buying guides, manuals, product pages, and more, making complex concepts accessible and engaging. His transition from academia to full-time writing reflects his passion for bridging technical expertise with clear, informative content. Since joining Bitcoinist, Aidan has written extensively about DeFi, dApps, AI, and meme coins, solidifying his grasp on emerging blockchain technologies. An early adopter, he began investing in Solana in 2020, further deepening his insights into crypto markets and innovation. Today, he combines hands-on experience with a sharp editorial instinct to help readers cut through hype, spot real trends, and make sense of a fast-moving space. This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy Center or Cookie Policy. I Agree Source: https://bitcoinist.com/best-crypto-to-buy-chatgpt-bitcoin-rate-cuts/
Share
BitcoinEthereumNews2025/09/19 01:15